^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiLi (adebrelimab)

    i
    Other names: SHR1316, SHR-1316, SHR 1316, HTI-1088, HTI-1316, HTI1088, HTI 1088, HTI 1316, HTI1316
    Associations
    News

    Trials

    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Pegylated Liposomal Doxorubicin Plus Adebrelimab with or Without Mirabegron in Relapsed Ovarian Cancer (NCT06791460)
    Phase 2/3
    Obstetrics & Gynecology Hospital of Fudan Unive...
    Not yet recruiting
    Last update posted :
    01/24/2025
    Initiation :
    02/15/2025
    Primary completion :
    02/14/2028
    Completion :
    02/14/2030
    CD8
    |
    PD-L1 expression
    |
    pegylated liposomal doxorubicin • AiRuiLi (adebrelimab) • mirabegron
    Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer (NCT06766019)
    Phase 2
    The First Affiliated Hospital with Nanjing Medi...
    Active, not recruiting
    Last update posted :
    01/09/2025
    Initiation :
    10/16/2024
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    CA 19-9
    |
    5-fluorouracil • AiRuiLi (adebrelimab)
    Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer (SHR-1316-SCLC-LN-001) (NCT06480864)
    Phase N/A
    Yunpeng Liu
    Recruiting
    Last update posted :
    01/06/2025
    Initiation :
    08/09/2024
    Primary completion :
    08/01/2025
    Completion :
    08/01/2026
    PD-L1 • IL6 • IL10
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • AiTan (rivoceranib) • etoposide IV • AiRuiLi (adebrelimab)
    Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N) (NCT05582499)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    12/27/2024
    Initiation :
    11/01/2022
    Primary completion :
    12/31/2024
    Completion :
    09/01/2025
    HER-2 • PGR • CD8 • FOXC1
    |
    Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)
    Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer (NCT06600841)
    Phase 2
    Fujian Cancer Hospital
    Not yet recruiting
    Last update posted :
    09/19/2024
    Initiation :
    10/01/2024
    Primary completion :
    03/01/2026
    Completion :
    10/01/2028
    HRD
    |
    PD-L1 expression • HRD
    |
    albumin-bound paclitaxel • AiRuiYi (fluzoparib) • AiRuiLi (adebrelimab)
    A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (NCT06385678)
    Phase 1/2
    Jiangsu HengRui Medicine Co., Ltd.
    Not yet recruiting
    Last update posted :
    04/26/2024
    Initiation :
    05/01/2024
    Primary completion :
    10/01/2025
    Completion :
    08/01/2026
    KRAS
    |
    cisplatin • carboplatin • pemetrexed • AiRuiLi (adebrelimab) • HRS-4642 • tizetatug rezetecan (SHR-A1921)
    Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401) (NCT06261125)
    Phase 2
    Mian XI
    Recruiting
    Last update posted :
    03/12/2024
    Initiation :
    03/10/2024
    Primary completion :
    06/30/2026
    Completion :
    06/30/2028
    IL6 • IL2RA • CD40
    |
    Lenvima (lenvatinib) • AiRuiLi (adebrelimab)
    Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02 (NCT05205200)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    02/08/2024
    Initiation :
    06/06/2022
    Primary completion :
    02/01/2025
    Completion :
    08/01/2026
    HER-2 • ER • PGR • SMARCA2
    |
    ER positive • HR positive • HER-2 negative • PGR positive
    |
    albumin-bound paclitaxel • fulvestrant • AiRuiKang (dalpiciclib) • AiRuiLi (adebrelimab)
    Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. (NCT05753826)
    Phase 2
    Fujian Cancer Hospital
    Recruiting
    Last update posted :
    02/06/2024
    Initiation :
    08/01/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2027
    HRD
    |
    AiRuiYi (fluzoparib) • AiRuiLi (adebrelimab)
    Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer (NCT06231017)
    Phase 2
    The First Affiliated Hospital of Zhengzhou Univ...
    Recruiting
    Last update posted :
    01/30/2024
    Initiation :
    01/19/2024
    Primary completion :
    01/19/2025
    Completion :
    01/19/2026
    BRAF
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • AiRuiLi (adebrelimab)
    Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment (NCT05132790)
    Phase N/A
    Shengjing Hospital
    Active, not recruiting
    Last update posted :
    01/03/2024
    Initiation :
    09/25/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2028
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • AiRuiKang (dalpiciclib) • AiRuiLi (adebrelimab)
    Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer (NCT06149767)
    Phase 2
    Fujian Cancer Hospital
    Not yet recruiting
    Last update posted :
    11/29/2023
    Initiation :
    01/01/2024
    Primary completion :
    02/01/2028
    Completion :
    03/01/2028
    PD-L1
    |
    cisplatin • paclitaxel • AiRuiLi (adebrelimab)